The APP Role in Advancing Anti-HER2 Treatment for Gastroesophageal Adenocarcinoma CME/CNE/CPE/IPCE Minneapolis Convention Center Thursday, October 15, 2026 | 9:30 am - 10:30 am CT Hybrid

https://na.eventscloud.com/website/98965/ Novel anti-HER2 regimens with unique safety profiles are poised to expand treatment options for patients with gastroesophageal adenocarcinoma (GEA). Designed specifically for advanced practice professionals, this 60-minute live symposium explores where new agents fit into care for human epidermal growth factor receptor 2 (HER2)-positive GEA and best approaches for toxicity management. Using real-world patient cases, faculty will offer insights on preventing and triaging adverse events. They will also offer advice on how to optimize workflows and coordinate care with the interprofessional team to improve patient outcomes. Don’t miss this opportunity to sharpen your clinical practice—reserve your spot today!